1-(3,4-dichlorophenyl)-5-methylpyrazole-4-carboxylic acid | 288252-19-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-(3,4-dichlorophenyl)-5-methylpyrazole-4-carboxylic acid
• 英文别名: 1-(3,4-Dichlorophenyl)-5-methyl-1H-pyrazole-4-carboxylic acid
• CAS: 288252-19-7
• 化学式: C₁₁H₈Cl₂N₂O₂
• mdl: MFCD09045268
• 分子量: 271.103
• InChiKey: VAUIOTDBWBFPHF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  55.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(3,4-dichlorophenyl)-5-methylpyrazole-4-carboxylic acid 、 5-amino-2-[4-(2-hydroxyethyl)piperazin-1-yl]benzonitrile 以the title compound (1.2 g) was obtained的产率得到1-(3,4-dichlorophenyl)-N-{3-cyano-4-[4-(2-hydroxyethyl)piperazin-1-yl]phenyl}-5-methylpyrazole-4-carboxamide
  参考文献：
  名称：

  Amide compounds and medicinal use thereof

  摘要：

  本发明涉及一种化合物，其化学式为其中R1为取代芳基，杂环芳基等，R2和R3为氢，烷基，卤素，羟基等，Q为N，CH等，W为氢，烷基，羟基羧基烷基等，X为卤素，氰基，硝基，氨基等，X'为氢，卤素，氰基，硝基，Y为烷基，羟基，烷氧基，巯基等及其盐，以及包含所述化合物的药物。本发明的化合物显示出对活化淋巴细胞增殖的优越抑制作用，并可用作各种自身免疫性疾病的预防或治疗剂。

  公开号：

  US07015218B1
• 作为产物：
  描述：

  1-(3,4-二氯苯基)-5-甲基-1H-吡唑-4-羧酸乙酯 生成 1-(3,4-dichlorophenyl)-5-methylpyrazole-4-carboxylic acid
  参考文献：
  名称：

  AMIDE COMPOUNDS AND MEDICINAL USE THEREOF

  摘要：

  公开号：

  EP1176140B1

文献信息

• [EN] PYRAZOLE COMPOUNDS AS CCR1 ANTAGONISTS<br/>[FR] COMPOSÉS DE PYRAZOLE COMME ANTAGONISTES DE CCR1
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2009137338A1

  公开（公告）日：2009-11-12

  Disclosed are compounds of the formula I which block the interaction of CCR1 and its ligands and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

  公开的是公式I的化合物，它们可以阻断CCR1与其配体的相互作用，因此可用于治疗通过CCR1的活性介导或维持的各种疾病和疾病，包括类风湿性关节炎和多发性硬化等自身免疫疾病。还公开了包括这些化合物的药物组合物，使用这些化合物治疗各种疾病和疾病的方法，制备这些化合物的过程以及在这些过程中有用的中间体。
• AMIDE DERIVATIVE AND USE THEREOF
  申请人：Ushio Hiroyuki

  公开号：US20130211075A1

  公开（公告）日：2013-08-15

  The present invention relates to a novel amide derivative. More specifically, the present invention provides a medicinal agent useful as a prophylactic or therapeutic agent for diseases, which relies on the production of cytokines from T cells, and which comprises an amide derivative or a pharmacologically acceptable salt thereof or a solvate of the derivative or the pharmacologically acceptable salt as an active ingredient. Provided is an amide derivative represented by general formula (I) [wherein each symbol is as defined in the description] or a pharmacologically acceptable salt thereof, or a solvate of the derivative or the pharmacologically acceptable salt.

  本发明涉及一种新型酰胺衍生物。更具体地说，本发明提供了一种药用剂，可用作依赖于T细胞产生细胞因子的疾病的预防或治疗剂，该药用剂包括酰胺衍生物或其药理学上可接受的盐或该衍生物或药理学上可接受的盐的溶剂的溶剂作为活性成分。提供的是由通式(I)所表示的酰胺衍生物[其中每个符号如描述中所定义]或其药理学上可接受的盐，或该衍生物或药理学上可接受的盐的溶剂。
• Pyrazole Compounds As CCR1 Antagonists
  申请人：Cook Brian Nicholas

  公开号：US20110230521A1

  公开（公告）日：2011-09-22

  Disclosed are compounds of the formula (I) which block the interaction of CCR1 and its ligands and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

  公开了式(I)的化合物，其可以阻止CCR1及其配体之间的相互作用，因此可用于治疗多种由CCR1的活性介导或维持的疾病和障碍，包括自身免疫性疾病，如类风湿性关节炎和多发性硬化症。还公开了包含这些化合物的制药组合物，使用这些化合物治疗各种疾病和障碍的方法，制备这些化合物的过程以及在这些过程中有用的中间体。
• PYRAZOLE COMPOUNDS AS CCR1 ANTAGONISTS
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2297112B1

  公开（公告）日：2013-04-03
• US7015218B1
  申请人：——

  公开号：US7015218B1

  公开（公告）日：2006-03-21